Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874189 | 0.93 | PTGS2 (0.33) | PLA2G2AGAAALDH1A1MAPTPTGS2 | |
| SCHEMBL4866690 | 0.91 | GAA (0.40) | GAAALDH1A1MAPTHPGDADAMTS5 | |
| SCHEMBL4872685 | 0.91 | PTGS2 (0.33) | PLA2G2AALDH1A1PTGS2ADAMTS5CCR2 | |
| SCHEMBL6982001 | 0.91 | ADAMTS5 (0.34) | PLA2G2AALDH1A1PTGS2ADAMTS5CCR2 | |
| SCHEMBL4869982 | 0.90 | ADAMTS5 (0.37) | GAAALDH1A1ADAMTS5CCR2HRH3 | |
| SCHEMBL4870404 | 0.89 | EPHX2 (0.34) | PLA2G2AGAAALDH1A1PTGS2ADAMTS5 | |
| SCHEMBL4866661 | 0.89 | GPR119 (0.33) | PLA2G2AGAAALDH1A1PTGS2ADAMTS5 | |
| SCHEMBL4875402 | 0.89 | PLA2G2A (0.32) | PLA2G2AGAAALDH1A1PTGS2ADAMTS5 | |
| SCHEMBL4874326 | 0.88 | EPHX2 (0.37) | ALDH1A1 | |
| SCHEMBL4876934 | 0.88 | PLA2G2A (0.32) | PLA2G2AALDH1A1PTGS2ADAMTS5CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | PLA2G2A 2510/4885GAA 4460/4885ALDH1A1 2504/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | PLA2G2A 2156/4885GAA 4250/4885ALDH1A1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.